Clinical characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait

Affiliations


Abstract

This is a retrospective single-center study of 417 consecutive patients with coronavirus disease 2019 (COVID-19) admitted to Jaber Al-Ahmad Hospital in Kuwait between February 24, 2020 and May 24, 2020. In total, 39.3% of patients were asymptomatic, 41% were symptomatic with mild/moderate symptoms, 19.7% were admitted to the intensive care unit (ICU). Most common symptoms in cohort patients were fever (34.3%) and dry cough (32.6%) while shortness in breath was reported in (75.6%) of ICU admissions. Reported complications requiring ICU admission included Sepsis (68.3%), acute respiratory distress syndrome (95.1%) and heart failure (63.4%). ICU patients were more likely to have comorbidities, in comparison to non-ICU patients, including diabetes (35.4% vs 20.3%) and hypertension (40.2% vs 26.9%). Mortality rate of cohort was 14.4% and mean age of death was 54.20 years (± 11.09) and 90% of death cases were males. Chest high-resolution computed tomography for ICU cases reveled multifocal large patchy areas of ground glass opacification mixed with dense consolidation. Cases admitted to ICU showed abnormal levels of markers associated with infection, inflammation, abnormal blood clotting, heart problems and kidney problems. Mean hospital stay for asymptomatic cases was 20.69 days ±8.57 and for mild/moderate cases was 21.4 days ±8.28. Mean stay in ICU to outcome for survivors was 11.95 days ±8.96 and for death cases 13.15 days ±10.02. In this single-center case series of 417 hospitalized COVID-19 patients in Kuwait 39.3% were asymptomatic cases, 41% showed mild/moderate symptoms and 18.7% were admitted to ICU with a mortality rate of 14.4%.

Conflict of interest statement

The authors have declared that no competing interests exist.


Figures


References

  1.  
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
  2.  
    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020. 10.1016/S1473-3099(20)30120-1 - DOI - PMC - PubMed
  3.  
    1. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020. 10.1001/jama.2020.2565 - DOI - PMC - PubMed
  4.  
    1. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020. 10.1016/j.jmii.2020.02.012 - DOI - PMC - PubMed
  5.  
    1. Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis. 2020;96:459–60. 10.1016/j.ijid.2020.05.071 - DOI - PMC - PubMed
  6.  
    1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9. 10.1038/s41586-020-2008-3 - DOI - PMC - PubMed
  7.  
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. 10.1001/jama.2020.1585 - DOI - PMC - PubMed
  8.  
    1. Ali H, Alshukry A, Bu Abbas M, Ali Y, Alahmad B, Al-Shammari AA, et al. Clinical Characteristics and Outcomes of Diabetic COVID-19 patients in Kuwait. medRxiv. 2020:2020.08.20.20178525. 10.1101/2020.08.20.20178525 - DOI
  9.  
    1. Alahmad B, Al-Shammari AA, Bennakhi A, Al-Mulla F, Ali H. Fasting Blood Glucose and COVID-19 Severity: Nonlinearity Matters. Diabetes Care. 2020. 10.2337/dc20-1941 . - DOI - PMC - PubMed
  10.  
    1. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–5. 10.1056/NEJMc2005073 - DOI - PMC - PubMed
  11.  
    1. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020. 10.1126/science.abc3517 - DOI - PMC - PubMed
  12.  
    1. Al-Shammari AAA, Ali H, Al-Ahmad B, Al-Refaei FH, Al-Sabah S, Jamal MH, et al. Real-time tracking and forecasting of the COVID-19 outbreak in Kuwait: a mathematical modeling study. medRxiv. 2020:2020.05.03.20089771. 10.1101/2020.05.03.20089771 - DOI
  13.  
    1. Al-Hasan A, Yim D, Khuntia J. Citizens' Adherence to COVID-19 Mitigation Recommendations by the Government: A 3-Country Comparative Evaluation Using Web-Based Cross-Sectional Survey Data. J Med Internet Res. 2020;22(8):e20634 10.2196/20634 - DOI - PMC - PubMed
  14.  
    1. LoPresti M, Beck DB, Duggal P, Cummings DAT, Solomon BD. The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature. Am J Hum Genet. 2020;107(3):381–402. 10.1016/j.ajhg.2020.08.007 - DOI - PMC - PubMed
  15.  
    1. Al-Mulla F, Mohammad A, Al Madhoun A, Haddad D, Ali H, Eaaswarkhanth M, et al. A comprehensive germline variant and expression analyses of ACE2, TMPRSS2 and SARS-CoV-2 activator FURIN genes from the Middle East: Combating SARS-CoV-2 with precision medicine. bioRxiv. 2020:2020.05.16.099176. 10.1101/2020.05.16.099176 - DOI
  16.  
    1. Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Bruselles A, et al. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. medRxiv. 2020:2020.04.03.20047977. 10.1038/s41431-020-0691-z - DOI - PMC - PubMed
  17.  
    1. Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020. 10.1002/jmv.25832 - DOI - PMC - PubMed
  18.  
    1. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–35. 10.1016/j.jmii.2020.04.015 - DOI - PMC - PubMed
  19.  
    1. Alahmad B, Kurdi H, Colonna K, Gasana J, Agnew J, Fox MA. COVID-19 stressors on migrant workers in Kuwait: cumulative risk considerations. BMJ Glob Health. 2020;5(7). 10.1136/bmjgh-2020-002995 . - DOI - PMC - PubMed
  20.  
    1. Al-Hasan A, Khuntia J, Yim D. Threat, coping and social distance adherence for COVID-19: Cross-continental comparison using online cross-sectional survey data. J Med Internet Res. 2020. 10.2196/23019 . - DOI - PMC - PubMed
  21.  
    1. Organization WH. Clinical management of COVID-19 Interim guidance. World Health Organization; 2020.
  22.  
    1. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33. 10.1001/jama.2012.5669 . - DOI - PubMed
  23.  
    1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100. 10.1111/j.1523-1755.2005.00365.x . - DOI - PubMed
  24.  
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
  25.  
    1. Bureau KCS. Population estimates in Kuwait by Age, Nationality and sex at 1L1L2019. 2019. Contract No.: 10/6/2020.
  26.  
    1. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv. 2020:2020.05.10.20097543. 10.1101/2020.05.10.20097543 - DOI
  27.  
    1. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. JAMA Netw Open. 2020;3(5):e2010182 10.1001/jamanetworkopen.2020.10182 - DOI - PMC - PubMed
  28.  
    1. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382(22):2158–60. 10.1056/NEJMe2009758 - DOI - PMC - PubMed
  29.  
    1. Spychalski P, Blazynska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020. 10.1016/S1473-3099(20)30246-2 - DOI - PMC - PubMed
  30.  
    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020. 10.1001/jama.2020.6775 - DOI - PMC - PubMed
  31.  
    1. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152 10.3389/fpubh.2020.00152 - DOI - PMC - PubMed
  32.  
    1. Rahimi-Levene N, Koren-Michowitz M, Zeidenstein R, Peer V, Golik A, Ziv-Baran T. Lower hemoglobin transfusion trigger is associated with higher mortality in patients hospitalized with pneumonia. Medicine (Baltimore). 2018;97(12):e0192 10.1097/MD.0000000000010192 - DOI - PMC - PubMed
  33.  
    1. Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(5):1233–4. 10.1111/jth.14820 - DOI - PMC - PubMed
  34.  
    1. Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020. 10.1056/NEJMc2013656 - DOI - PMC - PubMed
  35.  
    1. Garcia-Olive I, Sintes H, Radua J, Abad Capa J, Rosell A. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir Med. 2020;169:106023 10.1016/j.rmed.2020.106023 . - DOI - PMC - PubMed
  36.  
    1. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190–1. 10.1016/j.cca.2020.03.004 - DOI - PMC - PubMed
  37.  
    1. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128–32. 10.1016/j.ijid.2020.03.053 - DOI - PMC - PubMed
  38.  
    1. Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28(11):2687–97. 10.1093/ndt/gft320 - DOI - PMC - PubMed
  39.  
    1. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020. 10.1016/S2213-2600(20)30229-0 - DOI - PMC - PubMed
  40.  
    1. Awad A, Al-Nafisi H. Public knowledge of cardiovascular disease and its risk factors in Kuwait: a cross-sectional survey. BMC Public Health. 2014;14:1131 10.1186/1471-2458-14-1131 - DOI - PMC - PubMed
  41.  
    1. Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28(2):74–9. 10.1038/jhh.2013.55 . - DOI - PubMed
  42.  
    1. Alshukry A, Ali H, Ali Y, Al-Taweel T, Abu-farha M, AbuBaker J, et al. Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait. medRxiv. 2020:2020.06.14.20131045. 10.1101/2020.06.14.20131045 - DOI - PMC - PubMed